ArticleMolecular and cellular biochemistry2026
Long non-coding RNA SNHG6 promotes the proliferation of PASMCs cells through the miR-429/DUSP1 axis during early/subacute vascular responses to pulmonary embolism.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The regulatory mechanism of the long noncoding RNA SNHG6 in acute pulmonary embolism (APE) remains unclear. This study aimed to investigate the potential molecular mechanisms of SNHG6 in APE. This study established a clinical cohort comprising 120 APE patients and 120 healthy controls. It combined in vitro experiments using human pulmonary arterial smooth muscle cells (PASMCs) with in vivo experiments employing an autologous blood clot model of APE in Sprague-Dawley (SD) rats, measuring mean pulmonary artery pressure (mPAP). RT-qPCR was used to detect target gene expression. The CCK-8 assay evaluated cell proliferation, while the ELISA and western blot assays measured the relevant protein levels. The RIP assay and dual luciferase assay validated the target binding relationship. SNHG6 was significantly overexpressed in both serum samples from APE patients and lung tissues from model rats. In this exploratory case-control cohort, serum SNHG6 exhibited significant discriminatory capacity between APE patients and healthy controls (AUC = 0.9145) and showed an independent cross‑sectional association with APE status in multivariate analysis within this selected cohort. However, because serum SNHG6 was measured after diagnosis, this association should be interpreted strictly as a correlative finding rather than as evidence of prospective predictive or etiologic value. These findings require validation in clinically relevant populations with differential diagnoses. Mechanistic studies revealed that SNHG6 targeted and regulated miR-429, which in turn targeted DUSP1. In cultured PASMCs, SNHG6 acted as a competitive endogenous RNA to sequester miR-429, thereby releasing its suppression on the downstream target gene DUSP1. This upregulated the expression of proliferation-related molecules such as NOR-1 and PCNA, positively regulating PDGF-BB-induced PASMC cell proliferation. Animal experiments performed at a 7‑day subacute endpoint demonstrated that SNHG6 perturbation was associated with altered mean pulmonary artery pressure and early proliferative molecular markers during the early phase following embolic challenge. In cultured PASMCs, specific sponging of miR-429 by SNHG6 may attenuate the inhibitory effect of miR-429 on DUSP1, potentially contributing to exacerbated APE pathological manifestations.
Indexed as
Identifiers
42550429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.